Oxford Malaria vaccine proves highly effective in Burkina Faso trial
7 hours ago|Los Angeles, United States
Early trials show Oxford developers may have finally found an effective jab against the disease.
4 hours ago|United Kingdom
Oxford Malaria vaccine proves highly effective in Burkina Faso trial
Vaccine developed by scientists at Jenner Institute, Oxford, shows up to 77% efficacy in trial over 12 monthsA vaccine against malaria has been shown to be highly effective in trials in Africa, holding out the real possibility of slashing the death toll of a disease that kills 400,000 mostly small children every year.The vaccine, developed by scientists at the Jenner Institute of Oxford University, showed up to 77% efficacy in a trial of 450 chi…
New malaria vaccine is 77% effective at stopping infection in African trials -Report
alternativeafrica.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alternativeafrica.com Daily Mail and Mail on Sunday newspapers.
BREAKTHROUGH: Oxford vaccine shows 77% efficacy for malaria treatment
thecable.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecable.ng Daily Mail and Mail on Sunday newspapers.
Scientists Develop Malaria Vaccine That Could Be a Game-Changer
Malaria currently claims the lives of 400,000 children a year.
Why Global Citizens Should Care
Malaria kills thousands of people every year, primarily children under five on the African continent, but costs less than £1 to treat. In order to promote good health and wellbeing for all people, government leaders must invest in malaria prevention and treatment services. Join us by taking action on this issue here.
Scientists have developed a highly effective vaccine to prevent malaria, which kills hundreds of thousands of people each year, latest trials show.
The Jenner Institute of Oxford University announced that during their phase two trials concerning 450 children in Burkina Faso over 12 months, the vaccine achieved 77% efficacy, surpassing the World Health Organization’s (WHO) goal of 75% efficacy, according to the Guardian.